钙卫蛋白S100A8/S100A9在阿尔茨海默病中的研究进展

doi:10.3969/j.issn.1003-9198.2025.02.020

Abstract

Abstract: Alzheimer's disease(AD) is characterized by progressive memory loss. Based on the emerging theory of microbe-gut-brain axis, the changes in intestinal flora might activate the intestinal inflammation. Calprotectin, as a marker of intestinal inflammation, is a key substance in the brain-gut axis of AD. Its subunits S100A8 and S100A9 are also closely related to the Aβ theory and neuroinflammation theory in AD, respectively. Therefore, this article reviews the main functions of S100A8/S100A9 protein and its new research progress in AD-related pathogenesis, risk factors, prevention and treatment, in order to provide new research directions for the treatment of AD.

Key words: Alzheimer's disease, calprotectin, S100A9, S100A8

CLC Number:

R 749.16

WU Jinli, YANG Xiaojuan. Research progress of calprotectin S100A8/S100A9 in Alzheimer's disease[J]. Practical Geriatrics, 2025, 39(2): 197-201.

References

[1] WYSS-CORAY T, ROGERS J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature[J]. Cold Spring Harb Perspect Med, 2012, 2(1): a006346.
[2] MERIGHI S, NIGRO M, TRAVAGLI A, et al. Microglia and Alzheimer's disease[J]. Int J Mol Sci, 2022, 23(21): 12990.
[3] WANG X, SUN G, FENG T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression[J]. Cell Res, 2019, 29(10): 787-803.
[4] JUKIC A, BAKIRI L, WAGNER E F, et al. Calprotectin: from biomarker to biological function[J]. Gut, 2021, 70(10): 1978-1988.
[5] UBEDA C, VÁZQUEZ-CARRETERO M D, LUQUE-TIRADO A, et al. Fecal volatile organic compounds and microbiota associated with the progression of cognitive impairment in Alzheimer's disease[J]. Int J Mol Sci, 2022, 24(1): 707.
[6] SHEN L, LIAO L, CHEN C, et al. Proteomics analysis of blood serums from Alzheimer's disease patients using iTRAQ labeling technology[J]. J Alzheimers Dis, 2017, 56(1): 361-378.
[7] CONTINI C, SERRAO S, MANCONI B, et al. Salivary proteomics reveals significant changes in relation to Alzheimer's disease and aging[J]. J Alzheimers Dis, 2022, 89(2): 605-622.
[8] CONTINI C, OLIANAS A, SERRAO S, et al. Top-down proteomics of human saliva highlights anti-inflammatory, antioxidant, and antimicrobial defense responses in Alzheimer disease[J]. Front Neurosci, 2021, 15: 668852.
[9] HORVATH I, JIA X, JOHANSSON P, et al. Pro-inflammatory S100A9 protein as a robust biomarker differentiating early stages of cognitive impairment in Alzheimer's disease[J]. ACS chem Neurosci, 2016, 7(1): 34-39.
[10] LODEIRO M, PUERTA E, ISMAIL M A M, et al. Aggregation of the inflammatory S100A8 precedes Aβ plaque formation in transgenic APP mice: positive feedback for S100A8 and Aβ productions[J]. J Gerontol A Biol Sci Med Sci, 2017, 72(3): 319-328.
[11] KUMMER M P, VOGL T, AXT D, et al. Mrp14 deficiency ameliorates amyloid β burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing[J]. J Neuroscience, 2012, 32(49): 17824-17829.
[12] ZHANG X, SUN D, ZHOU X, et al. Proinflammatory S100A9 stimulates TLR4/NF-κB signaling pathways causing enhanced phagocytic capacity of microglial cells[J]. Immunol Lett, 2023, 255: 54-61.
[13] BAI Q, SUN D, ZENG Y, et al. Effect of proinflammatory S100A9 protein on migration and proliferation of microglial cells[J]. J Mol neurosci, 2023,73(11/12):983-995.
[14] HORVATH I, IASHCHISHYN I A, MOSKALENKO R A, et al. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies[J]. J Neuroinflammation, 2018, 15(1): 172.
[15] PANSIERI J, IASHCHISHYN I A, FAKHOURI H, et al. Templating S100A9 amyloids on Aβ fibrillar surfaces revealed by charge detection mass spectrometry, microscopy, kinetic and microfluidic analyses[J]. Chem Sci, 2020, 11(27): 7031-7039.
[16] KIM H J, CHANG K A, HA T Y, et al. S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model[J]. PLoS One, 2014, 9(2): e88924.
[17] YIN Y, GAO D, WANG Y, et al. Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling[J]. Proc Natl Acad Sci USA, 2016, 113(26): E3773-E3781.
[18] 周鑫, 白巧, 张小印, 等. S100A9通过TLR4/NF-κB信号通路活化星形胶质细胞促进炎症反应[J]. 基因组学与应用生物学, 2022, 41(5): 1103-1111.
[19] MA L, SUN P, ZHANG J C, et al. Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells[J]. Int J Mol Med, 2017, 40(1): 31-38.
[20] SIMARD J C, CESARO A, CHAPETON-MONTES J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB(1.)[J]. PLoS One, 2013, 8(8): e72138.
[21] VAN ZELLER M, DIAS D, SEBASTIÃO A M, et al. NLRP3 inflammasome: a starring role in amyloid-β-and tau-driven pathological events in Alzheimer's disease[J]. J Alzheimers Dis, 2021, 83(3):939-961.
[22] WU M, XU L, WANG Y, et al. S100A8/A9 induces microglia activation and promotes the apoptosis of oligodendrocyte precursor cells by activating the NF-κB signaling pathway[J]. Brain Res Bull, 2018, 143: 234-245.
[23] TIAN Y, CAO R, CHE B, et al. Proinflammatory S100A9 regulates differentiation and aggregation of neural stem cells[J]. ACS Chem Neurosci, 2020, 11(21): 3549-3556.
[24] LEBLHUBER F, GEISLER S, STEINER K, et al. Elevated fecal calprotectin in patients with Alzheimer's dementia indicates leaky gut[J]. J Neural Transm(Vienna), 2015, 122(9): 1319-1322.
[25] LOERA-VALENCIA R, ISMAIL M A M, GOIKOLEA J, et al. Hypercholesterolemia and 27-hydroxycholesterol increase S100A8 and RAGE expression in the brain: a link between cholesterol, alarmins, and neurodegeneration[J]. Mol Neurobiol, 2021, 58(12): 6063-6076.
[26] MAEKAWA T, SUGIMOTO M, KUME S, et al. Pathophysiological features in the brains of female Spontaneously Diabetic Torii(SDT) fatty rats[J]. J Vet Med Sci, 2022, 84(3): 330-337.
[27] WANG C, IASHCHISHYN I A, PANSIERI J, et al. S100A9-driven amyloid-neuroinflammatory cascade in traumatic brain injury as a precursor state for Alzheimer's disease[J]. Sci Rep, 2018, 8(1): 12836.
[28] TSAI S Y, SEGOVIA J A, CHANG T H, et al. Regulation TLR3 activation by S100A9[J]. J Immunol, 2015, 195(9): 4426-4437.
[29] IASHCHISHYN I A, GRUDEN M A, MOSKALENKO R A, et al. Intranasally administered S100A9 amyloids induced cellular stress, amyloid seeding, and behavioral impairment in aged mice[J]. ACS Chem Neurosci, 2018, 9(6): 1338-1348.
[30] HA T Y, CHANG K A, KIM J A, et al. S100A9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model[J]. PLoS One, 2010, 5(1): e8840.
[31] LERI M, CHAUDHARY H, IASHCHISHYN I A, et al. Natural compound from olive oil inhibits S100A9 amyloid formation and cytotoxicity: implications for preventing Alzheimer's disease[J]. ACS Chem Neurosci, 2021, 12(11): 1905-1918.
[32] FENG L, LI M, REN J, et al. Proteomic analysis reveals that di Dang decoction protects against acute intracerebral hemorrhage stroke in rats by regulating S100A8, S100A9 Col1a1, and Col1a2[J]. Neuropsychiatr Dis Treat, 2021, 17: 3301-3314.
[33] MAES T, MASCARÓ C, ROTLLANT D, et al. Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations[J]. PLoS One, 2020, 15(5): e0233468.
[34] ANDRADE-TALAVERA Y, CHEN G, PANSIERI J, et al. S100A9 amyloid growth and S100A9 fibril-induced impairment of gamma oscillations in area CA3 of mouse hippocampus ex vivo is prevented by Bri2 BRICHOS[J]. Prog Neurobiol, 2022, 219: 102366.
[35] CAO T, ZHOU X, ZHENG X, et al. Histone deacetylase inhibitor alleviates the neurodegenerative phenotypes and histone dysregulation in presenilins-deficient mice[J]. Front Aging Neurosci, 2018, 10: 137.
[36] LEE J, KUMAR S, LEE S Y, et al. Development of predictive models for identifying potential S100A9 inhibitors based on machine learning methods[J]. Front Chem, 2019, 7: 779.

Research progress of calprotectin S100A8/S100A9 in Alzheimer's disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	XIN Mengfan, FENG Meijiang. Advance in the diagnosis and treatment of Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 121-126.
[2]	MA Xiaoting, LIU Shanwen, YAO Linlin, BAO Runying, LI Yifeng, YANG Yifan, HU Hua. Mechanism of inflammaging in the progression of Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 202-206.
[3]	WANG Siya, YIN Shi. Effects of environmental exposure on cognitive impairment [J]. Practical Geriatrics, 2025, 39(1): 22-25.
[4]	WANG Bingsheng, CAO Shihua, CHENG Lingling, SHI Aili, SHI Yankai, YAO Jiani, LOU Xiajing, QI Wenhao, DONG Chaoqun, ZHU Xiaohong, WANG Bing, HE Danni, CHEN Yanfei. A nomogram prediction model for risk of Alzheimer’s disease among the elderly [J]. Practical Geriatrics, 2024, 38(12): 1246-1249.
[5]	SUN Li, YIN Weihong, JING Jun, QIAN Xiali. Effects of intraoperative subanesthetic dose of esketamine on early postoperative cognitive dysfunction in elderly patients undergoing spinal surgery [J]. Practical Geriatrics, 2024, 38(10): 1039-1043.
[6]	. [J]. Practical Geriatrics, 2023, 37(12): 1249-1254.
[7]	. [J]. Practical Geriatrics, 2023, 37(10): 984-988.
[8]	. [J]. Practical Geriatrics, 2023, 37(10): 1041-1043.
[9]	. [J]. Practical Geriatrics, 2023, 37(10): 1059-1063.
[10]	. [J]. Practical Geriatrics, 2023, 37(9): 869-872.
[11]	WANG Min, GUO Wen-jun, TANG Zhong-quan, ZHAO Xiao-min, OU Ting, LI Yun-tao. Association between hearing impairment and Alzheimer's disease: a Meta-analysis [J]. Practical Geriatrics, 2023, 37(9): 915-919.
[12]	. [J]. Practical Geriatrics, 2023, 37(8): 757-760.
[13]	. [J]. Practical Geriatrics, 2023, 37(5): 521-523.
[14]	. [J]. Practical Geriatrics, 2023, 37(4): 335-338.
[15]	. [J]. Practical Geriatrics, 2023, 37(3): 234-237.